Guillaume Connan

Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific.

Nautilus Biotech SA develops and markets innovative biotechnology products. The company focuses on improving and developing protein pharmaceuticals. The firm was founded in 1999 and is headquartered in Evry, France.

QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France.

Kaneka Eurogentec SA distributes reagents, kits and other related products for the biotechnology, pharmaceutical, and diagnostic sectors. It offers a range of services, from basic research in genomics and proteomics, to services associated with the development and manufacture of diagnostic and therapeutic products. The company was founded in 1985 and is headquartered in Seraing, Belgium.

Galien Développement SA provides management and financial services to pharmacies. The company was founded by Benoît Bouche on October 30, 2008 and is headquartered in Aix-en-Provence, France.

Chabé Limousines SAS provides luxury transportation and car leasing services. It offers limousines and other cars available for rent. The company was founded by Maurice Chabé in 1921 and is headquartered in Paris, France.

Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland.